From DCAT Value Chain Insights (VCI)
Waypoint Capital, the business enterprise for investments associated with the Bertarelli family, has appointed Christopher A. Viehbacher, former CEO of Sanofi, as managing partner of its US-based Gurnet Point Capital fund, which will have an initial allocation of $2 billion of capital to invest, with a mandate to lead the firm's global healthcare investment strategy. He joined the firm effective July 1, 2015.
Viehbacher will grow the existing team headquartered at Gurnet Point Capital's office in Cambridge, Massachusetts.
Fereydoun Firouz, who founded Gurnet Point Capital in 2013, was recently appointed as chairman and CEO designate of Ares Allergy Holdco Ltd., the firms' new global group of operating companies in the allergy immunotherapy sector.
Source: Gurnet Point Capital
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription